Getting latest data loading
Home / Morning Report / Morning Report

This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.

Morning Report - 10 January 2022

Yesterday’s UK 100 Leaders Price (p) % Chg
ANGLO AMERICAN PLC 3,257.0 2.9%
BHP GROUP PLC 2,305.5 2.7%
PRUDENTIAL PLC 1,320.0 2.7%
RIO TINTO PLC 5,212.0 2.6%
LEGAL & GENERAL GROUP PLC 307.8 2.6%
Yesterday’s UK  100 Laggards Price (p) % Chg
DIAGEO PLC 3874.5 -2.6%
B&M EUROPEAN VALUE RETAIL SA 605.8 -2.2%
SPIRAX-SARCO ENGINEERING PLC 15210.0 -2.1%
AVEVA GROUP PLC 3069.0 -2.1%
DECHRA PHARMACEUTICALS PLC 4470.0 -2.1%

 

Major World Indices Price % Chg 1 YEAR
UK 100 INDEX 7,485 0.5% 8.9%
DOW JONES INDUS. AVG 36,232 0.0% 16.5%
DAX INDEX 15,948 -0.7% 13.5%
NIKKEI 225 28,479 0.0% 1.2%
S&P/ASX 200 INDEX 7,447 -0.1% 10.2%

 

Commodities Units Price % Chg
WTI Crude Oil (Nymex) USD/bbl. 78.94 0.05%
Brent Crude (ICE) USD/bbl. 81.82 0.09%
Gold Spot USD/t oz. 1,793 -0.2%
Copper (Comex) USd/lb. 439 -0.4%
The UK 100 is called to open +20 points today at 7505.

4 hours; 10 Months

Click graph to enlarge

Markets Overview:

 

 

The UK 100 is called to open +20 points today at 7505. The UK 100 looks set to open modestly higher and above 7,500, this follows a spectacular start to the year last week for the UK’s Bluechip index.  The picture was not so strong to start the year Stateside, The Nasdaq lost around 5% last week, its sharpest decline in almost a year, as tech investors appeared to prepare for muted early hike to borrowing costs, following Hawkish Fed comments.  Asian markets were mixed on Monday as COVID-19 cases continue to rise sharply around the globe.  South Korea’s Kospi dipped 0.95% while Japan’s markets are closed for a public holiday.  The Shanghai Composite in China gained 0.30% and Hong Kong’s Hang Seng index surged 0.81%.

 

 

Company News & Broker Comments:

 

 

Company News:

Assura completes £105m in acquisitions in Q3 and they are on site for 2 new developments
Hikma Pharmaceuticals launches new 503B sterile compounding business.
Novartis are to exercise ensovibep option after encouraging COVID trial.
Plus 500 reports that their FY21 revenue was around $718m, with EBITDA of around $387m. They are to consider a new share buyback programme.
 
Spire Healthcare signs contract to help relieve pressure on NHS hospitals in England.

 

Broker Comments

Bernstein Downgrades National Grid to Market-perform from Outperform (11 Buys / 0 Holds / 0 Sells)
Citigroup Reinitiates Unilever with a Buy (5 Buys / 6 Holds / 1 Sell)

 

Reporting Today:

 

 

None

 

 

Reporting Tomorrow:

 

 

Electrocomponents

 

Games Workshop Group

 

 

In Focus Today:

 

 

EU  Unemployment Rate

 

 

This Week’s Ex-Dividends:

 

FTSE 100:

 

Next

SSE

Sage Group

Ashtead Group

 

FTSE 250:

 

Primary Health Properties

Shaftesbury

Dr. Martens

Future

 

For any help you may require placing trades or in terms of market information, put a call in to our trading floor – it’s all part of the service.


Back to Top

This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.


Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
.